Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Cottu

Showing results (111-120 of 140) with videos related to

Pageof 14
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 30, 2017
Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their MetastasesCharlotte K Y Ng, Francois-Clement Bidard, Salvatore Piscuoglio, et al.
Cell Reports. Medicine|January 10, 2026
Molecular and cellular composition changes after neoadjuvant letrozole and palbociclib in early luminal breast cancerPaul Cottu, Yann Kieffer, Jerome Lemonnier, et al.
British Journal of Cancer|June 17, 2022
Association between physical activity and neoadjuvant chemotherapy completion and pathologic complete response in primary breast cancer: the CANTO studyJennifer L Baker, Antonio Di Meglio, Arnauld S Gbenou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 21, 2014
Acquired resistance to endocrine treatments is associated with tumor-specific molecular changes in patient-derived luminal breast cancer xenograftsPaul Cottu, Ivan Bièche, Franck Assayag, et al.
European Journal of Cancer (Oxford, England : 1990)|March 26, 2022
Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancerSuzette Delaloge, Sylvain Dureau, Véronique D'Hondt, et al.
JNCI Cancer Spectrum|February 19, 2021
Characteristics and Outcome of SARS-CoV-2 Infection in Cancer PatientsClémence Basse, Sarah Diakite, Vincent Servois, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 5, 2024
Dose/Exposure Relationship of Exercise and Distant Recurrence in Primary Breast CancerDavide Soldato, Stefan Michiels, Julie Havas, et al.
Plos One|October 19, 2017
Prospective, multicenter French study evaluating the clinical impact of the Breast Cancer Intrinsic Subtype-Prosigna® Test in the management of early-stage breast cancersDelphine Hequet, Céline Callens, David Gentien, et al.
Genome Medicine|March 16, 2021
Molecular features of untreated breast cancer and initial metastatic event inform clinical decision-making and predict outcome: long-term results of ESOPE, a single-arm prospective multicenter studyCéline Callens, Keltouma Driouch, Anaïs Boulai, et al.
International Journal of Cancer|May 16, 2019
Real-life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME programWilliam Jacot, Pierre-Etienne Heudel, Julien Fraisse, et al.
Pageof 14

Showing results (111-120 of 140) with videos related to

Sort By:
Pageof 14
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 30, 2017
Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their MetastasesCharlotte K Y Ng, Francois-Clement Bidard, Salvatore Piscuoglio, et al.
Cell Reports. Medicine|January 10, 2026
Molecular and cellular composition changes after neoadjuvant letrozole and palbociclib in early luminal breast cancerPaul Cottu, Yann Kieffer, Jerome Lemonnier, et al.
British Journal of Cancer|June 17, 2022
Association between physical activity and neoadjuvant chemotherapy completion and pathologic complete response in primary breast cancer: the CANTO studyJennifer L Baker, Antonio Di Meglio, Arnauld S Gbenou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 21, 2014
Acquired resistance to endocrine treatments is associated with tumor-specific molecular changes in patient-derived luminal breast cancer xenograftsPaul Cottu, Ivan Bièche, Franck Assayag, et al.
European Journal of Cancer (Oxford, England : 1990)|March 26, 2022
Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancerSuzette Delaloge, Sylvain Dureau, Véronique D'Hondt, et al.
JNCI Cancer Spectrum|February 19, 2021
Characteristics and Outcome of SARS-CoV-2 Infection in Cancer PatientsClémence Basse, Sarah Diakite, Vincent Servois, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 5, 2024
Dose/Exposure Relationship of Exercise and Distant Recurrence in Primary Breast CancerDavide Soldato, Stefan Michiels, Julie Havas, et al.
Plos One|October 19, 2017
Prospective, multicenter French study evaluating the clinical impact of the Breast Cancer Intrinsic Subtype-Prosigna® Test in the management of early-stage breast cancersDelphine Hequet, Céline Callens, David Gentien, et al.
Genome Medicine|March 16, 2021
Molecular features of untreated breast cancer and initial metastatic event inform clinical decision-making and predict outcome: long-term results of ESOPE, a single-arm prospective multicenter studyCéline Callens, Keltouma Driouch, Anaïs Boulai, et al.
International Journal of Cancer|May 16, 2019
Real-life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME programWilliam Jacot, Pierre-Etienne Heudel, Julien Fraisse, et al.
Pageof 14